Browse by category

The number of metabolic and bariatric surgery procedures in the United States dropped below 200,000 in 2024 for the first time since 2020, a more than 20% decline from the prior year, according to research ‘‘Examining trends in the decline of bariatric surgery – an MBSAQIP analysis (Abstract ID: 4730)’, presented at the annual scientific meeting of the American Society for Metabolic and Bariatric Surgery. Tyler Cohn “After years of steady growth, the number of metabolic and b

Drawing on electronic health records from nearly 20 million patients with severe obesity, researchers from University of California San Diego find that GLP-1 prescriptions have grown exponentially from less than 4,600 prescriptions in 2018 to more than 1.4 million in 2025 - according to a new real-world analysis ‘Trends of bariatric surgery utilization in patients with severe obesity in the era of GLP-1 use for weight loss (Abstract ID: 4393)’ - presented at the annual scient

People who begin obesity treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) and then undergo metabolic and bariatric surgery achieve substantially greater weight loss than with the medications alone, according to research, ‘Bariatric surgery effectiveness after glp-1 agonist weight loss (abstract id: 4149)’, presented at the annual meeting of the American Society for Metabolic and Bariatric Surgery. “Patients are increasingly having surgery after GLP-1 therapy,

A new real-world analysis of more than 90,000 patients with obesity and type 2 diabetes finds metabolic and bariatric surgery is costs significantly less than weekly injections of GLP-1 drugs over a two-year period, according to research, ‘Understanding insurance-based differential healthcare costs for GLP-1ra versus bariatric surgery (abstract id: 4339)’, presented at the annual scientific meeting of the American Society for Metabolic and Bariatric Surgery. “As GLP-1 use bec

Metabolic and bariatric surgery offers significantly greater long-term protection against major adverse cardiovascular events (MACE, eg heart attack, stroke) and death than GLP-1 drugs in older adults with obesity and diabetes, according to real-world analysis study, ‘Cardiometabolic outcomes of metabolic surgery versus GLP-1 receptor agonists in older adults with diabetes and obesity (Abstract ID: 4719)’, presented at the annual meeting of the American Society for Metabolic

Most weight loss achieved using the injectable obesity drugs tirzepatide or semaglutide can be maintained by switching to daily oral orforglipron treatment, accord to research presented at the European Congress on Obesity in Istanbul, Turkey. The study is by Dr Louis J Aronne, Director of the Comprehensive Weight Control Center at Weill Cornell Medicine, New York, NY, and colleagues. While the efficacy of injectable therapies has been repeatedly proven in clinical trials, how